Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: There has been growing evidence on the utility of neoadjuvant FOLFIRINOX in borderline resectable (BR) or locally advanced (LA) pancreatic cancer. However, factors predicting survival in these patients remain to be identified, and we aimed to identify these prognostic factors. Methods: Between January 2013 and April 2017, patients with BR or LA pancreatic cancer who received FOLFIRINOX as their initial treatment were identified. Demographic data and clinical outcomes, including the chemotherapy response, conversion to resection, and survival, were reviewed. Results: A total of 117 patients with BR (n=39) or LA (n=78) pancreatic cancer were included. Of these patients, 29 (24.8%) underwent curative surgery, and R0 resection was achieved in 21 patients (72.4%). The median progression-free survival and overall survival time of all patients were 11.6 and 19.0 months, respectively. In resected patients, the median relapse-free survival and overall survival times were 14.8 and 28.6 months, respectively. In the multivariate Cox model, the lowest level of serum carbohydrate antigen 19-9 (CA 19-9) and resection after FOLFIRINOX were independent factors for improved overall survival. In the subgroup analysis of patients with initial 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) images, the maximum standardized uptake value (SUVmax) of the pancreatic mass was also shown as an independent factor for improved overall survival. Conclusions: In patients with BR or LA pancreatic cancer, FOLFIRINOX is a valuable neoadjuvant treatment that enables curative surgery in approximately one-quarter of patients and significantly improves overall survival. In these patients, the prognosis can be estimated using the lowest level of serum CA 19-9, operative status, and initial FDG-PET SUVmax.
Abstract
Background/Aims: There has been growing evidence on the utility of neoadjuvant FOLFIRINOX in borderline resectable (BR) or locally advanced (LA) pancreatic cancer. However, factors predicting survival in these patients remain to be identified, and we aimed to identify these prognostic factors. Methods: Between January 2013 and April 2017, patients with BR or LA pancreatic cancer who received FOLFIRINOX as their initial treatment were identified. Demographic data and clinical outcomes, including the chemotherapy response, conversion to resection, and survival, were reviewed. Results: A total of 117 patients with BR (n=39) or LA (n=78) pancreatic cancer were included. Of these patients, 29 (24.8%) underwent curative surgery, and R0 resection was achieved in 21 patients (72.4%). The median progression-free survival and overall survival time of all patients were 11.6 and 19.0 months, respectively. In resected patients, the median relapse-free survival and overall survival times were 14.8 and 28.6 months, respectively. In the multivariate Cox model, the lowest level of serum carbohydrate antigen 19-9 (CA 19-9) and resection after FOLFIRINOX were independent factors for improved overall survival. In the subgroup analysis of patients with initial 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) images, the maximum standardized uptake value (SUVmax) of the pancreatic mass was also shown as an independent factor for improved overall survival. Conclusions: In patients with BR or LA pancreatic cancer, FOLFIRINOX is a valuable neoadjuvant treatment that enables curative surgery in approximately one-quarter of patients and significantly improves overall survival. In these patients, the prognosis can be estimated using the lowest level of serum CA 19-9, operative status, and initial FDG-PET SUVmax.
참고문헌 (30)
- Siegel RL, "Cancer Statistics, 2017", CA Cancer J Clin, 67, pp.7~30 (2017)
- Heinemann V, "Perioperative management of pancreatic cancer", Ann Oncol, 19(Suppl 7), pp.vii273~vii278 (2008)
- Stathis A, "Advanced pancreatic carcinoma : current treatment and future challenges", Nat Rev Clin Oncol, 7, pp.163~172 (2010)
- Ryan DP, "Pancreatic adenocarcinoma", N Engl J Med, 371, pp.1039~1049 (2014)
- Versteijne E, "Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer", Br J Surg, 105, pp.946~958 (2018)
- Jang JY, "Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer : a prospective, randomized, open-label, multicenter phase 2", 3 trial, 2018, pp.268, 215~222
- Conroy T, "FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer", N Engl J Med, 364, pp.1817~1825 (2011)
- Schneitler S, "Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection", World J Gastroenterol, 21, pp.6384~6390 (2015)
- Gostimir M, "Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer : a case report and review", BMC Cancer, 16, pp.786~ (2016)
- Murphy JE, "Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma : a phase 2 clinical trial", JAMA Oncol, 4, pp.963~969 (2018)
- Yoo C, "Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma : improved efficacy compared with gemcitabine-based regimen", Oncotarget, 8, pp.46337~46347 (2017)
- Boone BA, "Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer", J Surg Oncol, 108, pp.236~241 (2013)
- Ma W, "Quantitative(18)F-FDG PET analysis in survival rate prediction of patients with nonsmall cell lung cancer", Oncol Lett, 16, pp.4129~4136 (2018)
- Diao W, "The prognostic value of SUV(max)measuring on primary lesion and ALN by(18)F-FDG PET or PET", CT in patients with breast cancer, 2018, pp.105, 1~7
- Lee JW, "Prognostic value of metabolic tumor volume and total lesion glycolysis on preoperative 18F-FDG PET", CT in patients with pancreatic cancer, 2014, pp.55, 898~904
- Tempero MA, "Pancreatic Adenocarcinoma, Version 2. 2017, NCCN Clinical Practice Guidelines in Oncology", J Natl Compr Canc Netw, 15, pp.1028~1061 (2017)
- Lee JC, "Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer : using cumulative relative dose intensity", Eur J Cancer, 76, pp.125~133 (2017)
- Eisenhauer EA, "New response evaluation criteria in solid tumours : revised RECIST guideline(version 1. 1)", Eur J Cancer, 45, pp.228~247 (2009)
- Lausen B, "Maximally selected rank statistics", Biometrics, 48, pp.73~85 (1992)
- Suker M, "FOLFIRINOX for locally advanced pancreatic cancer : a systematic review and patient-level meta-analysis", Lancet Oncol, 17, pp.801~810 (2016)
- Rombouts SJ, "Systematic review of resection rates and clinical outcomes after FOLFIRINOXbased treatment in patients with locally advanced pancreatic cancer", Ann Surg Oncol, 23, pp.4352~4360 (2016)
- Faris JE, "FOLFIRINOX in locally advanced pancreatic cancer : the Massachusetts General Hospital Cancer Center experience", Oncologist, 18, pp.543~548 (2013)
- Hosein PJ, "A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma", BMC Cancer, 12, pp.199~ (2012)
- Todaka A, "Nationwide multicenter observational study of FOLFIRINOX chemotherapy in 399 patients with unresectable or recurrent pancreatic cancer in Japan", Pancreas, 47, pp.631~636 (2018)
- Boeck S, "Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer", Oncology, 70, pp.255~264 (2006)
- Ballehaninna UK, "The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma : an evidence based appraisal", J Gastrointest Oncol, 3, pp.105~119 (2012)
- Robert M, "Retrospective analysis of CA19-9 decrease in patients with metastatic pancreatic carcinoma treated with FOLFIRINOX or gemcitabine in a randomized phase III study(ACCORD11", PRODIGE4), 2017, pp.93, 367~376
- Ferrone CR, "Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer", Ann Surg, 261, pp.12~17 (2015)
- Wagner M, "CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma", Eur Radiol, 27, pp.3104~3116 (2017)
- Zhu D, "Prognostic value of 18FFDG-PET", CT parameters in patients with pancreatic carcinoma: a systematic review and meta-analysis, 2017, pp.96, e7813~